Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Niskanen, L, Leiter, LA, Franek, E, Weng, J, Damci, T, Muñoz-Torres, M, Donnet, J-P, Endahl, L, Skjøth, TV & Vaag, A 2012, 'Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial', European Journal of Endocrinology, bind 167, nr. 2, s. 287-94. https://doi.org/10.1530/EJE-12-0293

APA

Niskanen, L., Leiter, L. A., Franek, E., Weng, J., Damci, T., Muñoz-Torres, M., Donnet, J-P., Endahl, L., Skjøth, T. V., & Vaag, A. (2012). Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. European Journal of Endocrinology, 167(2), 287-94. https://doi.org/10.1530/EJE-12-0293

CBE

MLA

Vancouver

Author

Niskanen, Leo ; Leiter, Lawrence A ; Franek, Edward ; Weng, Jianping ; Damci, Taner ; Muñoz-Torres, Manuel ; Donnet, Jean-Paul ; Endahl, Lars ; Skjøth, Trine Vang ; Vaag, Allan. / Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes : a randomised trial. I: European Journal of Endocrinology. 2012 ; Bind 167, Nr. 2. s. 287-94.

Bibtex

@article{edfea2c8a9944b51bb4763093fe8147b,
title = "Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial",
abstract = "Insulin degludec/insulin aspart (IDegAsp) is a soluble co-formulation of insulin degludec (70%) and insulin aspart (IAsp: 30%). Here, we compare the efficacy and safety of IDegAsp, an alternative IDegAsp formulation (AF: containing 45% IAsp), and biphasic IAsp 30 (BIAsp 30).",
keywords = "Adolescent, Adult, Aged, Biphasic Insulins, Chemistry, Pharmaceutical, Diabetes Mellitus, Type 2, Drug Administration Schedule, Drug Combinations, Female, Hemoglobin A, Glycosylated, Humans, Hypoglycemic Agents, Insulin Aspart, Insulin, Isophane, Insulin, Long-Acting, Male, Metformin, Middle Aged, Solubility, Treatment Outcome, Young Adult",
author = "Leo Niskanen and Leiter, {Lawrence A} and Edward Franek and Jianping Weng and Taner Damci and Manuel Mu{\~n}oz-Torres and Jean-Paul Donnet and Lars Endahl and Skj{\o}th, {Trine Vang} and Allan Vaag",
year = "2012",
doi = "10.1530/EJE-12-0293",
language = "English",
volume = "167",
pages = "287--94",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes

T2 - a randomised trial

AU - Niskanen, Leo

AU - Leiter, Lawrence A

AU - Franek, Edward

AU - Weng, Jianping

AU - Damci, Taner

AU - Muñoz-Torres, Manuel

AU - Donnet, Jean-Paul

AU - Endahl, Lars

AU - Skjøth, Trine Vang

AU - Vaag, Allan

PY - 2012

Y1 - 2012

N2 - Insulin degludec/insulin aspart (IDegAsp) is a soluble co-formulation of insulin degludec (70%) and insulin aspart (IAsp: 30%). Here, we compare the efficacy and safety of IDegAsp, an alternative IDegAsp formulation (AF: containing 45% IAsp), and biphasic IAsp 30 (BIAsp 30).

AB - Insulin degludec/insulin aspart (IDegAsp) is a soluble co-formulation of insulin degludec (70%) and insulin aspart (IAsp: 30%). Here, we compare the efficacy and safety of IDegAsp, an alternative IDegAsp formulation (AF: containing 45% IAsp), and biphasic IAsp 30 (BIAsp 30).

KW - Adolescent

KW - Adult

KW - Aged

KW - Biphasic Insulins

KW - Chemistry, Pharmaceutical

KW - Diabetes Mellitus, Type 2

KW - Drug Administration Schedule

KW - Drug Combinations

KW - Female

KW - Hemoglobin A, Glycosylated

KW - Humans

KW - Hypoglycemic Agents

KW - Insulin Aspart

KW - Insulin, Isophane

KW - Insulin, Long-Acting

KW - Male

KW - Metformin

KW - Middle Aged

KW - Solubility

KW - Treatment Outcome

KW - Young Adult

U2 - 10.1530/EJE-12-0293

DO - 10.1530/EJE-12-0293

M3 - Journal article

C2 - 22660026

VL - 167

SP - 287

EP - 294

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 2

ER -

ID: 36878777